Literature DB >> 8327655

Leukemia, lymphoma, and multiple myeloma after pelvic radiotherapy for benign disease.

P D Inskip1, R A Kleinerman, M Stovall, D L Cookfair, O Hadjimichael, W C Moloney, R R Monson, W D Thompson, J Wactawski-Wende, J K Wagoner.   

Abstract

The relationship between exposure to sparsely ionizing radiation and mortality due to cancers of hematopoietic and lymphopoietic tissues was studied among 12,955 women treated for benign gynecological disorders at any of 17 hospitals in New England or New York State and followed for an average of 25 years; 9770 women were treated by radiation (intracavitary 226Ra, external-beam X rays), while 3185 were treated by other methods, including curettage, surgery, and hormones. The average age at treatment was 46.5 years, and the mean dose to active bone marrow among irradiated women was 119 cGy. Forty deaths due to acute, myelocytic, or monocytic leukemia were observed among irradiated women. This number was 70% higher than expected based on U.S. mortality rates [standardized mortality ratio (SMR) = 1.7; 90% confidence interval (CI) 1.3-2.3]. A deficit was recorded among nonirradiated women, based on three observed deaths (SMR = 0.5; 90% CI 0.1-1.2). A well-defined gradient in the SMR with dose among exposed women was not detected. The SMR was highest within 5 years after irradiation but remained elevated even after 30 years. The temporal pattern differed by subtype of leukemia: excess mortality due to chronic myelocytic leukemia occurred almost exclusively within the first 15 years, whereas the SMR for acute leukemia, though also elevated, varied little over time. Cancers of lymphoreticular tissue occurred more often than expected based on U.S. mortality rates, but not appreciably differently for irradiated and nonirradiated women. There was little or no evidence of effects attributable to radiotherapy for chronic lymphocytic leukemia [relative risk (RR) = 1.1; 90% CI 0.5-3.0], Hodgkin's disease (RR = 0.9; 90% CI 0.3-3.2), non-Hodgkin's lymphoma (RR = 0.9; 90% CI 0.6-1.6), or multiple myeloma (RR = 0.6; 90% CI 0.3-1.4). These results corroborate previous findings indicating that acute and myelocytic leukemias are the most prominent malignancies after exposure to sparsely ionizing radiation, occurring in excess shortly after irradiation, and that lymphomas are either not caused by radiation or are induced only rarely.

Entities:  

Mesh:

Year:  1993        PMID: 8327655

Source DB:  PubMed          Journal:  Radiat Res        ISSN: 0033-7587            Impact factor:   2.841


  15 in total

Review 1.  Hormesis, an update of the present position.

Authors:  Lennart Johansson
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-04-26       Impact factor: 9.236

Review 2.  Quantitative modeling of chronic myeloid leukemia: insights from radiobiology.

Authors:  Tomas Radivoyevitch; Lynn Hlatky; Julian Landaw; Rainer K Sachs
Journal:  Blood       Date:  2012-02-21       Impact factor: 22.113

3.  Long-term health effects of persistent exposure to low-dose lr192 gamma-rays.

Authors:  Hongbo Li; Lin Wang; Zujun Jiang; Li Li; Zhifang Xiao; Zenghui Liu; Shuang Zhang; Hui Jin; Lei Su; Yang Xiao
Journal:  Exp Ther Med       Date:  2016-09-07       Impact factor: 2.447

4.  Sex differences in the incidence of chronic myeloid leukemia.

Authors:  Tomas Radivoyevitch; Gradimir M Jankovic; Ramon V Tiu; Yogen Saunthararajah; Robert C Jackson; Lynn R Hlatky; Robert Peter Gale; Rainer K Sachs
Journal:  Radiat Environ Biophys       Date:  2013-12-13       Impact factor: 1.925

Review 5.  Radiotherapy for benign disease; assessing the risk of radiation-induced cancer following exposure to intermediate dose radiation.

Authors:  Stephanie R McKeown; Paul Hatfield; Robin J D Prestwich; Richard E Shaffer; Roger E Taylor
Journal:  Br J Radiol       Date:  2015-10-14       Impact factor: 3.039

Review 6.  Ionising radiation and cancer risks: what have we learned from epidemiology?

Authors:  Ethel S Gilbert
Journal:  Int J Radiat Biol       Date:  2009-06       Impact factor: 2.694

Review 7.  A review of dosimetry studies on external-beam radiation treatment with respect to second cancer induction.

Authors:  X George Xu; Bryan Bednarz; Harald Paganetti
Journal:  Phys Med Biol       Date:  2008-06-09       Impact factor: 3.609

8.  Cancer mortality following radiotherapy for benign gynecologic disorders.

Authors:  Ritsu Sakata; Ruth A Kleinerman; Kiyohiko Mabuchi; Marilyn Stovall; Susan A Smith; Rita Weathers; Jean Wactawski-Wende; Diane L Cookfair; John D Boice; Peter D Inskip
Journal:  Radiat Res       Date:  2012-08-02       Impact factor: 2.841

9.  Risk of non-Hodgkin lymphoma after radiotherapy for solid cancers.

Authors:  Clara J Kim; D Michal Freedman; Rochelle E Curtis; Amy Berrington de Gonzalez; Lindsay M Morton
Journal:  Leuk Lymphoma       Date:  2012-12-31

10.  Current understanding of lifestyle and environmental factors and risk of non-hodgkin lymphoma: an epidemiological update.

Authors:  Bryan A Bassig; Qing Lan; Nathaniel Rothman; Yawei Zhang; Tongzhang Zheng
Journal:  J Cancer Epidemiol       Date:  2012-09-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.